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A bstract: Recently we described a group o f purine derivatives based on theophylline structure with acetic acid 
moiety. Studies in a group of these compounds demonstrated their analgesic and anti-inflammatory properties.
Taking into account wide spectrum o f theophylline derivatives activity and searching for their new properties. 
the aim of the study was to evaluate safety o f newly synthesized derivatives in hum an keratinocytes model. The 
effect o f new  purine derivatives with acetic acid moiety: 2-(8-methoxy-1,3-dimethyl-2,6-dioxo-purin-7-yl) 
acetic acid and 2-(1,3-dim ethyl-2,6,8-trioxo-9H-purin-7-yl) acetic acid on proliferation rate and the ability of 
keratinocytes to m igration was carried out. The results clearly demonstrate that purine derivatives with acetic 
acid moiety did not affect basic keratinocytes functions. Our compounds do not inhibit cells proliferation rate 
as well as their ability to migration. It can be therefore concluded that new purine derivatives with acetic acid 
moiety are safe versus normal cells. This observation opens up additional prospects in searching for their new 
applications.
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Theophylline (1,3-dim ethyl-7H-purine-2,6- 
dione) is a xanthine, belonging to the group of 
purine alkaloids. Naturally occurs in cocoa beans, 
tea leaves as well as in coffee grains and cola seeds 
(1). This alkaloid was firstly discovered at the end of 
the nineteenth century in tea leaves and since begin­
nings of the twentieth century is produced syntheti­
cally on a large scale (2, 3). Theophylline is the only 
compound among methylxanthines currently used in 
the treatment. Due to its immunomodulatory, anti­
inflammatory, bronchoprotective and spasmolytic 
properties is used in bronchial asthma and chronic 
obstructive pulmonary disease (COPD) therapy (4­
6). Theophylline is also known for its diuretic prop­
erties. Its involvement in the extension of vascular 
and airway smooth muscle has been also described 
in the literature (2).
Conducted for many years research, has shown 
that this methylxanthine affects many processes 
occurring inside the cells. However, its specific
mechanism of action is still unknown. It has been 
shown that theophylline is a non-specific phospho­
diesterase inhibitor as well as an antagonist of the 
adenosine receptors (7). Immunomodulatory func­
tion of this alkaloid is manifested mainly by increas­
ing secretion of IL-10 by peripheral blood mononu­
clear cells (8), enhancing PPARy level in 
eosinophils (9) and induction of neutrophils and T 
lymphocytes apoptosis (2). Theophylline used at 
low doses causes also activation of histone deacety- 
lases, and thereby can enhance the anti-inflammato­
ry effect of corticosteroids (10).
Over recent years in the search for new drugs 
the most important are modifications of previously 
known structures. Alterations of parent theophylline 
core fit very well into this “drug repurposing” trend. 
Due to the interesting properties and chemical struc­
ture, this compound is modified for many years (11). 
In the course of our search for new biologically 
active compounds based on theophylline structure
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we described a group of purine derivatives with 
acetic acid moiety (12). Among the evaluated com­
pounds, 2-(8-methoxy-1,3-dimethyl-2,6-dioxo- 
purin-7-yl)acetic acid (purine-2,6-dione derivative, 
1 and 2-(1,3-dim ethyl-2,6,8-trioxo-9H-purm -7- 
yl)acetic acid (purine-2,6,8-trione derivative, 2 
(Fig. 1) have been tested for anti-inflammatory and 
analgesic activity in the in vivo models. Compound 
1 decreased neutrophils count and inhibited intensi­
ty of early vascular permeability in rats. This deriv­
ative displayed also high activity in the zymosan- 
induced peritonitis. Furthermore, this compound 
significantly inhibited TN F-a production in plasma 
of rats with endotoxemia (13). Compounds 1 and 2 
displayed also analgesic activity confirmed in two 
applied in vivo models: the writhing syndrome and 
the formalin tests (12, 13, our unpublished data). 
Considering interesting pharmacological properties 
of our new compounds we decided to check their 
safety in the in vitro model.
Our study was aimed to assess the cytotoxic 
effect of new purine derivatives with acetic acid 
moiety in human keratinocytes model. We evaluat­
ed also the influence of evaluated compounds on 
keratinocytes ability to migration, one of the basic 
parameters which characterize phenotype of these 
cells.
EXPERIM ENTAL
Isolation and culture of prim ary hum an skin ker- 
atinocytes
The human keratinocytes were isolated from skin 
fragments derived from plastic surgeries with the con­
sent of the Jagiellonian University Bioethics Committee 
(No.: KBET/72/B/2008) and informed, written consent 
was obtained from all study participants. Isolation pro­
cedure was performed according to the protocol 
described by Drukala et al. (14). Cells were cultured in 
a defined, serum-free, KGM-Gold medium (Lonza) at 
37OC temperature, 5% CO2 atmosphere and 95% 
humidity. Culture medium was changed every 48 h. For 
the experiments, cells between 3-7 passages were used. 
For monitoring cells morphology Nikon Eclipse TS100 
phase contrast microscope was used.
Purine derivatives w ith acetic acid moiety synthe­
sis
Purine-2,6-dione (1) and purine-2,6,8-trione 
(2) derivatives were synthesized as described previ­
ously (13, 15).
Com pounds preparation
Compounds 1 and 2 were diluted in the culture 
medium from stock solution (1 mg/mL prepared in
Figure 1. Structures o f investigated compounds 1 and 2
Figure 2. M orphology o f keratinocytes after 72 h  incubation with 1 or 2 at concentration 200 ^M  in com parison to control conditions. 
Pictures were taken using inverted bright field, m icroscope with IM C contrast
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Figure 3. The effect o f investigated compounds 1 or 2 on keratinocytes proliferation rate. Cells were cultured with growing concentrations 
(5-75 pM  -  A  and 100-200 pM  -  B) o f 1 or 2 and counted after 48 h  (A) and 48/72 h  (B) o f incubation. Bars represent m ean value o f cells 
proliferation expressed in percentages with S.D. Experiments were run in duplicates.* p < 0.05; ** p < 0.01
dimethyl sulfoxide, DMSO; Sigma-Aldrich) to the 
working concentration: 5, 15, 25, 50, 75, 100, 150, 
200 pM). The medium containing an amount of 
DMSO equivalent to the highest applied 1 and 2 
concentration (0.5%e) was taken as a solvent control. 
At this concentration, DMSO did not exert an effect 
on human keratinocytes basic features and functions 
like morphology, proliferation, viability and motili­
ty (data not shown).
Proliferation assay
For proliferation assay, cells were seeded into 
12-well plates at an initial density of 5 x 103 
cells/cm2 (10 x 103 cells/cm2 at lower compound con­
centrations), in KGM-Gold medium and culture for 
24 h in standard conditions. After 24 h, the culture 
medium was replaced with a fresh one containing 1 
or 2. Unstimulated cells represented an experiment 
control. Cells were incubated with tested com­
pounds for 24 and 72 h and then harvested by
trypsinization and counted using Scepter™ 2.0 Cell 
Counter (Millipore).
Time lapse-m onitoring of m ovem ent of individ­
ual cells
Keratinocytes were seeded into 12-well plates 
at a density of 5 x103 cells/cm2 and cultured in 
KGM-Gold medium in standard conditions. After 
the cells reach the appropriate density, culture medi­
um was replaced with medium containing com­
pounds 1 or 2 at 5, 15, 25, 50 or 75 pM concentra­
tions and then cultured for 24 h. After that time, 
cells migration was recorded for 90 min at 90 s time 
intervals, using the LEICA DMI 6000B microscope. 
The quantitative analysis of cells movement param­
eters was performed using the Hiro 1.0.0.4 software 
(16). For each data point 50 cells were analyzed. 
The cell trajectories were presented in circular dia­
grams with the starting point of each trajectory situ­
ated at the plot center.
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Statistical analysis
Statistical analysis was performed with 
GraphPad Prism 6.0 (GraphPad Software, 
Inc., San Diego, USA). Comparisons of 
parameters between experimental conditions 
were performed using Student’s t-test for 
unpaired data. Experiments were run in trip­
licates. The results are presented as the 
means with standard deviation. Statistical 
significance was assumed as p < 0.05 or p < 
0.01.
RESULTS 
Purine derivatives with acetic acid moiety 
do not affect the viability and morphology 
of human skin keratinocytes
Compounds 1 and 2 were previously 
demonstrated to possess analgesic properties 
(12, our unpublished data). The derivative 1 
showed anti-inflammatory activity in in vivo 
tests (13). Therefore, we decided to investi­
gate whether these new purine derivatives 
with acetic acid moiety may also affect the 
cell basic functions and features in in vitro 
experiments. In order to evaluate their safe­
ty, human skin keratinocytes cultures were 
used. Microscopic observation of cells after 
addition of the studied compounds showed 
that neither 1 nor 2 had an effect on ker- 
atinocytes morphology. As illustrated in 
Figure 2, compounds administrated in the 
highest tested concentration, after 72 h long 
culture did not affect cells phenotype. There 
were also no differences in the cells mor­
phology after 24, 48 and 72 h of incubation 
with analyzed derivatives. Moreover, we 
found that new purine derivatives with 
acetic acid moiety were not toxic to human 
skin keratinocytes (data not shown).
Purine derivatives with acetic acid moiety 
slightly affect the proliferation rate of 
human skin keratinocytes
A number of compounds tested for tox­
icity appear to have no effect on cell viabili­
ty. On the other hand, the same substances 
may affect the rate of cell proliferation, 
causing loss of division capacity. Since we 
found that the investigated compounds 
turned out non-toxic towards epithelial cells, 
we decided to explore their impact on ker- 
atinocytes proliferation. Performed experi­
ments have shown that analyzed derivatives
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used at lower concentrations (5-75 |±M) did not 
affect keratinocytes proliferation rate. After 48 h of 
incubation, both compounds did not cause statisti­
cally significant changes in ability to cell divisions 
(Fig. 3A). Keratinocytes proliferation rate after 48 h 
slightly increased after incubation in higher concen­
tration (100-200 |âM) of purine derivatives with 
acetic acid moiety but only in case of purine-2,6- 
dione this effect is statistically significant (Fig. 3B). 
Further prolongation of keratinocytes culture in the 
presence of tested compounds for 72 h led to an 
increase in proliferation rate. Three days long cells 
incubations in the higher concentrations of purine-
2,6-dione and purine-2,6,8-trione resulted in prolif­
eration promoting effect (Fig. 3B). As illustrated in 
Fig. 3B, this effect is statistically significant for both 
compounds.
Purine derivatives w ith acetic acid moiety have 
no effect on hum an skin keratinocytes m igration
Because increased proliferation activity of 
epithelial cells is associated with changes in the
migration activity of these cells, in the next step we 
decided to explore the impact of purine derivatives 
with acetic acid moiety on keratinocytes motility. 
Keratinocytes in relation with their function in the 
epithelium, and particularly in the process of wound 
healing, are cells that possess high migratory activi­
ty. Also in our experimental model this effect has 
been confirmed. The movement trajectories of indi­
vidual cells under control conditions are presented 
in a circular diagram (Fig. 4Aa). Surprisingly, we 
observed that our compounds did not change ker- 
atinocytes motility. Cells incubated in the presence 
of 1 (Fig. 4Ab-f) or 2 (Fig. 4Bg-k) in concentrations 
ranging from 5 to 75 |±M showed no changes in 
migration activity. The analysis of keratinocytes 
movement parameters under the action of evaluated 
derivatives revealed that there cannot be observed 
any differences between various experimental con­
ditions. Table 1 shows the individual results of 
quantitative analysis parameters such as length of 
cells trajectory, displacement, average speed of cells 
movement, rate of cells displacement and the most
Figure 4. The influence of investigated compounds 1 or 2 on keratinocytes m igration activity. Cells were cultured with growing concen­
trations (5-75 ^M ) o f 1 (A) or 2 (B) and single trajectories o f individual cells were analyzed. Circular diagrams represents cells migrating 
after 1 or 2 treatm ent in 5 ^M  (b,g) 15 ^M  (c,h), 25 ^M  (d,i), 50 ^M  (e,j), 75 ^M  (f,k) concentration and in control conditions (a). The 
beginning of single cell trajectory is m arked on the graph at the point 0 .0  o f the coordinate system. 50 cells were analyzed in each exper­
imental condition
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imaging -  coefficient of displacement efficiency. 
Thus, may be concluded that the effects of 1 and 2 
on keratinocytes proliferation rate were not paral­
leled by changes in migration activity. The 
increased proliferation rate after 1 or 2 treatment did 
not correlate with human skin keratinocytes migra­
tion activity.
DISCUSSION AND CONCLUSION
Theophylline is a drug used in the clinic for 
over 100 years. Although described adverse effects, 
mainly due to its narrow therapeutic index, this drug 
is still intensively studied. Particular interest of 
many research groups is modifying the main theo­
phylline structure and seeking for its new properties. 
In accordance with the principle of “an old drug -  
new applications”, scientists are trying to find new 
possibilities of theophylline derivatives exploitation. 
In these stream undoubtedly fit searching in the 
group of purine derivatives with acetic acid moiety.
Newly synthesized and described compounds 
exhibited anti-inflammatory and analgesic activity 
in the in vivo experiments (12, 13, our unpublished 
data). This provided a rationale for further explo­
ration of their new biological functions. Because 
contemporary science moving away from carrying 
screening with the use of laboratory animals and 
instead proposing in vitro models we decided to 
check the safety profile of our compounds in human 
keratinocytes model. These epithelial cells that con­
stitute about 90% of the cells found in the epidermis, 
are a very good model for safety assessment of new 
compounds and testing their cytotoxicity (17-19).
Our research has shown that new purine deriv­
atives with demonstrated anti-inflammatory and 
analgesic activity have proven to be safe in tests car­
ried out in cellular model. The derivative of purine-
2,6-dione as well as purine-2,6,8-trione were not 
cytotoxic towards epithelial cells - keratinocytes. 
This is very interesting especially in the context of a 
well-described in the literature effect of theophylline 
on the keratinocytes viability. Already many years 
ago, Chopra described that these cells treated with 
theophylline beginning to enter the apoptosis path­
way (20). It was also dem onstrated that this 
methylxanthine, in contrast to other immunomodu- 
lators, does not affect the reduction of T-cells- 
induced keratinocytes apoptosis (21). On the other 
hand, some research reported that methylxathines 
and among them theophylline co-administrated with 
anti-cancer drugs may protect cells by diminishing 
mutagenic effects of chemotherapeutics (22).
Regardless of the described theophylline actions, 
our studies indicate that modifications within the 
parent compound structure are translated into its 
new biological properties and in case of new purine 
derivatives with acetic acid moiety may result in 
limiting its toxic effects towards human epidermal 
cells.
Rapid proliferation is the one of main features 
of keratinocytes. Moreover, proliferation dynamics 
and migration rate of these cells are very important 
for recovery of homeostasis of epithelial tissue dur­
ing wound healing. Our experiments indicate that 
new purine derivatives with acetic acid moiety 
administrated at lower concentrations did not affect 
keratinocytes proliferation rate as well as its migra­
tion efficiency. A number of factors that, depending 
on therapeutic purpose, may inhibit keratinocytes 
proliferation as well as those that may enhance it, 
are described in scientific reports. The search for 
substances and methods limiting epithelial cell pro­
liferation is carried out in the studies of pathogene­
sis diseases like psoriasis or atopic dermatitis (23­
27). From the wound healing point of view com­
pounds increasing proliferation rate are sought. 
Experiments conducted in the framework of new 
purine derivatives with acetic acid moiety safety 
testing showed that our compounds given in higher 
concentrations are capable of enhancing ker- 
atinocytes proliferation rate. It is well known that 
not cytotoxic and cytostatic towards epidermis cells 
compounds, and at the same time slightly inducing 
rate of cell division, may be potentially used in 
wound healing therapies (28-30). Taking into 
account purine-2,6-dione and purine-2,6,8-trione 
derivatives anti-inflammatory and newly discovered 
proliferation promoting properties, it appears that 
these compounds may have potential application in 
supporting the process of scarring.
During the study it was shown that evaluated 
compounds are not toxic and do not affect the move­
ment parameters of keratinocytes. However, we 
were able to identify their proliferation-promoting 
effect. Considering that these compounds are safe 
relative to keratinocytes, it seems very interesting 
their further evaluation particularly in the context of 
their proliferation-promoting and anti-inflammatory 
effects.
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